# A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

> **NCT05249829** · PHASE2,PHASE3 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 3548 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** mRNA-1273.529
- **BIOLOGICAL:** mRNA-1273
- **BIOLOGICAL:** mRNA-1273.214

## Key facts

- **NCT ID:** NCT05249829
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-16
- **Primary completion:** 2023-06-23
- **Final completion:** 2023-06-23
- **Target enrollment:** 3548 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05249829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05249829, "A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05249829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*